

1 **The potential effect of romosozumab on perioperative management for**  
2 **instrumentation surgery**

3

4 Koji Ishikawa<sup>1,2,3\*</sup>, Soji Tani<sup>1</sup>, Tomoaki Toyone<sup>1</sup>, Koki Tsuchiya<sup>1</sup>, Tomoko Towatari<sup>1</sup>, Yusuke Oshita<sup>4</sup>, Ryo  
5 Yamamura<sup>1</sup>, Takashi Nagai<sup>1,5</sup>, Toshiyuki Shirahata<sup>6</sup>, Katsunori Inagaki<sup>1</sup>, Yoshifumi Kudo<sup>1</sup>

6

7 <sup>1</sup> Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan

8 <sup>2</sup> Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan

9 <sup>3</sup> Department of Orthopaedic Surgery, Duke University, North Carolina, USA

10 <sup>4</sup> Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital, Kanagawa, Japan

11 <sup>5</sup> Department of Rehabilitation Medicine, School of Medicine, Showa University, Tokyo, Japan

12 <sup>6</sup> Department of Orthopaedic Surgery, Showa University Koto Toyosu Hospital

13

14 **\*Corresponding author:** Koji Ishikawa (K.I)

15 Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan

16 Address: Building No.6, room517, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan

17 Tel: +81 3 3784 8543 Fax: +81 3 3784 9005

18 Email: [koji.ishikawa@med.showa-u.ac.jp](mailto:koji.ishikawa@med.showa-u.ac.jp), ORCID ID: 0000-0003-3689-5662

19

20 **Competing Interest Statement**

21 K.I. and T.N. received a speaking fee from Amgen.

## 22 **Abstract**

23 **Background:** Age-related changes in bone health increase the risk for complications in elderly patients  
24 undergoing orthopedic surgery. Osteoporosis is a key therapeutic target that needs to be addressed to  
25 ensure successful instrumentation surgery. The effectiveness of pharmacological interventions in  
26 orthopedic surgery, particularly the new drug romosozumab, is still unknown. We aim to evaluate the  
27 effect of 3-month romosozumab treatment on biomechanical parameters related to spinal instrumentation  
28 surgery, using the Quantitative Computed Tomography (QCT)-based Finite Element Method (FEM).

29 **Methods:** This open-labeled, prospective study included 81 patients aged 60 to 90 years, who met the  
30 osteoporosis criteria and were scheduled for either romosozumab or eldecacitol treatment. Patients were  
31 assessed using blood samples, dual-energy absorptiometry (DXA), and QCT. Biomechanical parameters  
32 were evaluated using FEM at baseline and 3 months post-treatment. The primary endpoints were  
33 biomechanical parameters at 3 months, while secondary endpoints included changes in regional  
34 volumetric bone mineral density around the pedicle (P-vBMD) and vertebral body (V-vBMD).

35 **Results:** Romosozumab treatment led to significant gains in P-vBMD, and V-vBMD compared to  
36 eldecacitol at 3 months. Notably, the romosozumab group showed greater improvements in all  
37 biomechanical parameters estimated by FEM at 3 months compared to the eldecacitol group.

38 **Conclusion:** Romosozumab significantly increased the regional vBMD as well as biomechanical  
39 parameters, potentially offering clinical benefits in reducing post-operative complications in patients with  
40 osteoporosis undergoing orthopedic instrumentation surgery. This study highlights the novel advantages  
41 of romosozumab treatment and advocates further research on its effectiveness in perioperative  
42 management.

## 43 **Introduction**

44 Recent medical advancements have significantly increased life expectancy, leading to a rise in the number  
45 of aged patients undergoing surgeries (1–3). The significant shift in the aging population highlights  
46 osteoporosis as an enormous problem in orthopedic surgery due to its impact on postoperative  
47 complications (4–6).

48 Osteoporosis, a global health concern, is not only an essential therapeutic target for extending healthspan,  
49 but also lifespan (7–9). Recent research has further investigated the links of osteoporosis with orthopedic  
50 surgery, aiming to optimize operative outcomes (10–13). Specifically, if instrumentation spinal surgery is  
51 indicated, adequate risk stratification, including bone health, is advocated to ensure optimal and safe  
52 outcomes, since bone fragility exacerbates postoperative complications such as loosening, junctional  
53 failure, and cage subsidence, potentially resulting in revision surgery. Indeed, previous studies have  
54 reported that 25-60% of patients with osteoporosis experienced postoperative complications, even  
55 following successful instrumentation surgery (14–16).

56 While dual-energy absorptiometry (DXA) is a reliable method for assessing bone health, earlier imaging  
57 studies highlight the heterogeneity of the bone mineral density (BMD) inside the vertebra, which is  
58 overlooked by DXA measurement (17). Additionally, recent findings indicate that regional volumetric  
59 bone mineral density (vBMD) around an implant, as measured by QCT, demonstrates stronger  
60 correlations with both intraoperative screw fixation and postoperative complications, including screw  
61 loosening and cage subsidence, compared to areal bone mineral density (aBMD) assessed by DXA.  
62 (6,18,19). Furthermore, Keaveney et al. demonstrated the superiority of CT-based biomechanical  
63 analysis over BMD testing alone in terms of predicting reoperation following spinal instrumentation  
64 surgery (5). Thus, a multidisciplinary approach including bone health assessment of the heterogeneity of  
65 the BMD in the vertebra as well as biomechanical analysis is recommended prior to surgery to an ensure  
66 optimal and safe outcome.

67 Pharmacologic therapy could play an important role in perioperative bone management for facilitating  
68 bone health, but its effectiveness for orthopedic implant surgery has not been systematically investigated  
69 (12,20). The possible advantage of osteoporosis treatments for instrumentation surgery, including  
70 teriparatide and bisphosphonate, specifically addressing issues like screw loosening and adjacent vertebral  
71 fractures, have been reported previously (18,20–23). Although the contribution of BMD to cage  
72 subsidence is described, to the best of our knowledge, there is no study examining the effects of  
73 osteoporosis treatment for cage subsidence (19). A significant challenge in biomechanical implant  
74 analysis in the clinical, particularly during pharmacological intervention, is the inability to conduct  
75 damage or destruction analysis. Our recent *in silico* biomechanical analysis using Finite Element Method  
76 (FEM) challenges these limitations, and showed that a 12-month course of denosumab treatment (an anti-  
77 RANKL antibody) is potentially beneficial for reducing postoperative screw loosening following spinal  
78 instrumentation surgery (18). This study lays the groundwork for understanding the impact of  
79 osteoporosis treatment on optimizing outcomes in instrumentation surgery. However, considering the  
80 onset of postoperative complications within the initial few months after surgery, there is a pressing need  
81 for treatments that show benefits quickly following administration (16).

82 Although increasing evidence suggests that osteoporosis treatment positively impacts orthopedic surgery,  
83 no standard approach exists for perioperative management. A substantial hurdle when incorporating  
84 osteoporosis treatments into surgical strategies is the extended time frame, typically around a year,  
85 required for the improvement of bone structure after treatment initiation. However, for patients requiring  
86 immediate surgery, delaying procedures for the benefits of osteoporosis treatment is not a viable option.  
87 This presents a challenge in determining the optimal timing and effectiveness of osteoporosis treatment  
88 for patients in need of immediate surgical intervention. Romosozumab may offer a solution to this issue,  
89 given that previous reports have shown its potential to increase BMD shortly after treatment  
90 administration in terms of both imaging and bone biopsy assessment (24–26).

91 Thus, we aim to evaluate the effects of a 3-month romosozumab treatment on spinal instrumentation  
92 surgery using QCT-based FEM. We have extended our earlier FEM methods to cover analysis for the

93 risk of cage subsidence, a major complication that occur in 5-50% of cases following surgery and is  
94 linked with negative clinical outcomes (19). Here, we first demonstrated the potential benefits of short-  
95 term romosozumab treatment in improving bone health and reducing postoperative complications in  
96 patients with osteoporosis undergoing spinal instrumentation surgery.

97

## 98 **Methods**

### 99 **Study subjects**

100 This was an open-labeled prospective study of ambulatory patients 60 to 90 years of age who met the  
101 osteoporosis criteria (27). Between March 2019 and March 2021, 226 patients who were scheduled for  
102 Romosozumab (Romo) or Eldecalcitol (ELD) treatment, were assessed for inclusion, of which 81 patients  
103 participated in the present study. The exclusion criteria were patients with illnesses affecting bone and  
104 calcium metabolism or bone disorders other than osteoporosis, any malignant conditions, fresh fracture,  
105 scheduled surgery, severe renal dysfunction or history of cardiovascular events. The patients were  
106 divided into two groups based on their treatment (Romo: 69 patients, ELD: 12 patients). All patients  
107 received daily eldecalcitol (0.75 µg) and / or calcium (400-800 mg) except for four patients in the Romo  
108 group. These four exceptions were decided by physicians based on their baseline serum calcium levels to  
109 prevent hypercalcemia. The medication compliance related to eldecalcitol and calcium was assessed at  
110 each visit and it was confirmed that all patients consumed > 90% of the drugs over the course of the  
111 study. The study was approved by the local ethics committees of Yamanashi Red Cross Hospital and in  
112 accordance with the precepts of the Declaration of Helsinki. All patients provided informed consent  
113 before participation.

### 114 **Assessments**

115 We measured the spine-areal BMD (spine-aBMD) using DXA (L1-4) (Hologic QDR series: Hologic,  
116 Waltham, MA) at baseline and 6 months. All DXA measurements were analyzed by a radiologist at a  
117 central site. The regional vBMD around the pedicle (P-vBMD) and vertebral body (V-vBMD) as well as

118 biomechanical parameters were measured by QCT-based FEM at baseline and 3 months. The intra- and  
119 inter-observer coefficients of variation of BMD assessments have been previously described (6,18,28)  
120 The serum levels of albumin, calcium, and phosphorus as well as estimated glomerular filtration rate  
121 (eGFR) were evaluated at baseline. The bone turnover markers including serum levels of TRACP-5b and  
122 total-P1NP were assessed at baseline, then at 3 and 6 months following treatment. The primary endpoints  
123 were the biomechanical parameters at 3 months. Secondary endpoints included the changes in regional  
124 vBMD and bone turnover markers throughout the study.

### 125 **Three-dimensional volumetric bone mineral density**

126 The details of the measurement of vBMD have been described in previous studies (6,18,29,30). CT data  
127 were acquired with a SOMATOM Definition AS+ multidetector-row CT scanner (Aquilion 16; Toshiba  
128 Medical Systems, Otawara, Japan) using predefined scanning conditions (x-ray energy, 120 kV; x-ray  
129 current, SD20; rotation speed, 0.5 s/rot; beam pitch, 0.95). For QCT scanning, a phantom (Mindways,  
130 Austin, TX, USA) was placed underneath the patients for BMD calibration, thereby ensuring  
131 measurement quality throughout the study. The vBMD at the vertebral body and pedicle (reference  
132 vertebra L4) was measured using MECHANICAL FINDER (Research Center of Computational  
133 Mechanics; version 10.0, Tokyo, Japan) (Fig.1, Fig. S1). We selected the L3 vertebra if the L4 vertebra  
134 had a grade 2 or 3 fracture by using a semiquantitative method (31).

### 135 **Finite Element Methods**

136 Biomechanical parameters related to spinal instrumentation including compression strength (CS), pullout  
137 strength of the screw (POS) and cage subsidence strength (CSS) were evaluated by QCT-based FEM  
138 using MECHANICAL FINDER. The FEM modeling methods were based on previous studies and are  
139 shown in Fig.1 and Movie.S1-4 (18,32). Briefly, finite element models of the L4 vertebrae were  
140 constructed from the CT data and examined for the CS (Movie.S2). Then, a pedicle screw and cage were  
141 placed according to the spinal fusion surgery so as to evaluate the POS and CSS (18) (Movie.S3, 4). In  
142 the CSS model, a banana-shaped PEEK (polyetheretherketone) cage, which was created using

143 Metasequoia 4 (tetraface Inc., Tokyo, Japan), was set 4-mm behind the anterior edge of the upper  
144 endplate vertebrae according to the spinal fusion surgery so as to assess the risk of cage subsidence. A  
145 compressive displacement was applied to the cage at the cranial end of the vertebrae at ramped  
146 displacement increments of 0.02 mm / step. The predicted CCS was identified by a rapid decrease in the  
147 force-displacement curve or a rapid increase in the failure elements. The detailed finite element models  
148 and materials properties are provided in Table S1.

### 149 **Statistical analysis**

150 Fisher's exact test and the Mann-Whitney U test were used to compare differences between the 2 groups.  
151 Dunn's test was used for multiple comparisons. The correlations between each parameter were  
152 determined using Spearman's rank coefficients. Statistical analyses were performed using Stat Flex Ver. 6  
153 (Artech, Tokyo). All statistical tests were two tailed and results with P-values < 0.05 were considered  
154 statistically significant.

155

## 156 **Results**

### 157 **Patients and baseline demographics**

158 Sixty-six patients in the Romo-group (66 / 69 patients, 95.7%) and 10 patients in the ELD-group (10 / 12  
159 patients, 83.3%) completed the 6 months study follow-up (Romo: 66 / 69 [ 95.7% ], ELD: 10/12 [83.3%],  
160 P = ns)(Fig.S1). The reasons for the discontinued study were as follows; loss of motivation (1 patient in  
161 Romo, 2 patients in ELD), hospital administration related to vascular event (1 patient in Romo), death  
162 unrelated to treatment (1 patient in Romo). Table 1 shows the demographics and baseline characteristics  
163 of the groups. Serum TRACP-5b and P1NP were higher in the ELD group, presumably due to a  
164 difference in the prior treatment history, but the difference was not significant. BMD measured by DXA  
165 and QCT was equivalent in the two groups.

### 166 **Safety**

167 The patients observed to undergo adverse events were 21 (30.4%) in the Romo and no patients in the  
168 ELD (Fig. S3). Injection-site reactions such as redness, tenderness and swelling were reported by 16  
169 patients (23.2%) in Romo group. These reactions were well recognized at the initial injection (50.0%).  
170 Among the patients who had injection-site reactions, five patients (7.3%) experienced these reactions  
171 multiple times during the study (Fig. S4). One (1.5%) patient had hypocalcemia and one (1.5%) patient  
172 had hypercalcemia in the Romo group, both of which were of mild severity and asymptomatic.  
173 Gastroenteritis was observed in one (1.5%) patient. Two (2.9 %) patients in the Romo group had severe  
174 adverse events including one stroke and one death leading to treatment discontinuation, neither of which  
175 was thought to be related to the treatment.

#### 176 **Changes in bone turnover markers showed dual effects of Romosozumab**

177 The changes in the total P1NP and TRACP-5b levels are shown in Fig. S5. In the Romo group, the P1NP  
178 level reached its highest value at 3 months ( $P < 0.001$ , vs. Baseline), followed by a gradual decrease at 6  
179 months. Percentage changes from baseline of total P1NP was higher in the Romo group compared to the  
180 ELD group at 3 and 6 months (all  $P < 0.001$ ). The P1NP level decreased significantly over the course of  
181 the study in the ELD group (3 months;  $P < 0.01$ , 6 months;  $P < 0.01$ , vs. baseline). The TRACP-5b levels  
182 decreased significantly in both groups at 3 and 6 months, and there was no significant difference between  
183 groups.

#### 184 **Greater increases in regional BMD in Romo group**

185 The median percentage changes from baseline in aBMD by DXA at 6 months was 6.61% (Q1/Q3: 2.62 /  
186 12.7) in the Romo group and 0.91% (0.25 / 2.06) in the ELD group ( $P < 0.001$ ) (Fig. S6a). The 3D-  
187 modeling of the vertebrae demonstrates the heterogeneity of the vertebral BMD that is undetectable by  
188 DXA measurement. (Fig. 2a). The difference between the groups observed at 6 months was already  
189 identifiable in the regional BMD measurement at 3 months (Fig. 2b-e). The Romo group exhibited  
190 significantly greater increases in regional BMD including the vertebral body and pedicle at 3 months  
191 compared to the ELD group (V-vBMD; Romo vs. ELD: 10.43% [4.39 / 16.77] vs. 1.54% [-4.45 / 2.48], P



192 < 0.001 and P-vBMD; 12.75% [4.94 / 18.08] vs. 2.22% [-0.35 / 5.13], P < 0.001) (Fig. 2f). Remarkably,  
193 treatment with romosozumab resulted in noticeable BMD increases not only within the inner pedicle  
194 region (corresponding to ROI of the P-vBMD) but also on the cortical surface of the inner pedicle (Fig.  
195 2b, d, e). Similarly, the BMD around the endplate, the corresponding area for cage placement in spinal  
196 fusion surgery, increased following romosozumab treatment (Fig. 2d, e). In treatment-naïve patients,  
197 while the results were consistent, the group differences were more evident (aBMD: 9.05% [5.13 / 14.4]  
198 vs. 0.95% [0.57 / 2.56], P < 0.001, V-vBMD: 12.84% [5.75 / 20.88] vs. 1.33% [-5.37 / 2.11], P < 0.0001  
199 and P-vBMD: 12.75% [4.94 / 17.49] vs. 1.22% [-0.44 / 5.30], P < 0.001,) (Figs. 2g, S6b).

### 200 **Significant improvement in biomechanical parameters in the Romo group**

201 Greater gains in the percentage changes from baseline were observed in the Romo group than in the ELD  
202 group in all of the biomechanical parameters (compression strength: 11.49% [2.04 / 22.55] vs. 0.74% [-  
203 2.85 / 6.89], pullout strength: 20.00% [9.09 / 33.33] vs. 0.00% [0.0 / 10.00], cage subsidence strength:  
204 11.19% [3.08 / 25.31] vs. -0.55% [-6.36 / 4.30], P < 0.01, P < 0.001, P < 0.001, respectively) (Fig. 3d).  
205 This results were bolstered by the distribution of yield risk and crushed element, which further illustrates  
206 the significant improvement following romosozumab treatment (Fig. 3a-c). The findings are consistent  
207 among treatment-naïve patients (compression strength: 13.60% [1.81 / 24.1] vs. 2.50% [-3.74 / 7.21],  
208 pullout strength: 20.00% [0.00 / 33.33] vs. 0.0% [0.0 / 8.89], cage subsidence strength: 18.27% [3.26 /  
209 28.11] vs. -1.97% [-6.61 / 4.38], P < 0.01, P < 0.01, P < 0.001, respectively) (Fig. 3d). Collectively, these  
210 findings suggest a potential contribution of 3 months of romosozumab treatment to the reduction of  
211 postoperative complications in instrumentation surgery.

### 212 **Regional vBMD had the most significant correlations with biomechanical parameters**

213 Local areal contribution around the implant, as displayed in each biomechanical analysis in Figure 3, led  
214 us to examine the correlation between biomechanical parameters with various BMD assessments. The  
215 correlations between the BMD and biomechanical parameters are summarized in Table 2. While the

216 aBMD demonstrated mild or no correlations with the biomechanical parameters, the strongest correlations  
217 were observed with the regional vBMD across all parameters in both groups.

218

## 219 **Discussion**

220 Despite the longstanding recognition through intensive research of osteoporosis as a risk factor for  
221 postoperative complications in orthopedic instrumentation surgery, these complications persist as a  
222 primary concern and critical priority for surgeons. This challenge is becoming more prominent with the  
223 worldwide increase in the aged population (33,34).

224 One significant limitation of biomechanical implant assessment for surgery, particularly in clinical  
225 practice, is the inability to conduct damage or destruction analysis, a method traditionally applied in  
226 animal and human cadaver research (35,36). This issue, therefore, presents a difficulty for surgeons when  
227 they are trying to determine the effectiveness of osteoporosis treatments in mitigating postoperative  
228 complications. Our *in silico* biomechanical analysis, utilizing patient QCT data collected during  
229 treatment, offers a broader perspective, and contributes novel insights to the field of bone and implant  
230 research.

231 In this study, romosozumab treatment was associated with larger gains in spine BMD at 6 months, as  
232 measured by DXA, consistent with previous trials (24,37,38). The difference observed at 6 months was  
233 already evident at 3 months, confirmed by regional vBMD in both the vertebral body and pedicle.  
234 Remarkably, this change began soon after treatment administration, associated with improvements in  
235 FEM-estimated biomechanical parameters such as vertebral compression strength, screw pullout strength,  
236 and cage subsidence strength. It is noteworthy that these parameters are closely linked with common  
237 postoperative complications, suggesting the potential benefits of romosozumab for perioperative  
238 management. The notable gains in the both the BMD and FEM-estimated parameters are likely attributed  
239 to the dual mechanisms of romosozumab, namely, the enhancement of bone formation and reduction of  
240 bone resorption, as demonstrated by the evaluation of bone turnover markers (39–41).

241 Several strategies have been proposed for managing osteoporosis in patients undergoing spinal surgery,  
242 with a broad consensus emphasizing the need for preoperative bone health assessment (11–13). If poor  
243 bone health condition is detected, initiation of pharmacological treatment is recommended. Moreover,  
244 considering the risk of postoperative complications in patients with osteoporosis, Lubelski and colleagues  
245 suggest postponing surgery in order to strengthen the bone prior to the procedure (12). In the light of  
246 increases in regional vBMD and potential risk reduction post-surgery shortly after the treatment  
247 administration in this study, romosozumab may emerge as a valuable preoperative therapeutic option.  
248 This is particularly significant, given that the effectiveness of most osteoporosis therapies is typically not  
249 recognized until one or two years after treatment.

250 Limitations in DXA's capacity to predict future fractures and postsurgical complications, arising from  
251 factors like BMD heterogeneity in the vertebra, osteophyte formation, articular facet hypertrophy, and  
252 aortic calcification, are further supported in the present study (5,6,42). We found that all of the  
253 biomechanical parameters exhibit their strongest correlations with vBMD around the implant. This  
254 implies a significant contribution of region-specific vBMD in postoperative complications. As potential  
255 DXA limitations like overestimation of BMD is prevalent in patients with a spinal disorder, evaluation of  
256 regional vBMD might yield more clinical utility in assessing the risk of surgery. Furthermore, with the  
257 distinct post-treatment changes in regional BMD, along with superior correlations of corresponding  
258 regional vBMD with biomechanical parameters, understanding the therapeutic effects of specific regional  
259 vBMD could offer potentially valuable insights over traditional DXA assessment for surgeons. However,  
260 this hypothesis needs further investigation.

261 Previous studies on the effects of romosozumab showed increases in both cortical BMD and cortical  
262 thickness (25,43). Genant et al. reported that most significant changes in the cortical area predominantly  
263 occur in the endocortical region (44). Furthermore, histomorphometry analysis of bone biopsies from a  
264 clinical trial showed that the anabolic effect in the initial 2 months of romosozumab treatment mainly  
265 arises on the endocortical surface, leading to a 18.3% increase in the mineralizing surface compared to a  
266 4.1% increase in the trabecular bone (26,45). Even though we did not scrutinize parameters related to the

267 cortical and endocortical area due to their ambiguous definition and the limited resolution of imaging  
268 studies, we did find that the vBMD in the pedicle responded more favorably to treatment than in the  
269 vertebral area. These insights could potentially support previously mentioned studies, given that P-  
270 vBMD region of interest presumably includes the endocortical area, whereas V-vBMD mainly comprises  
271 trabecular bone.

272 Consistent with a previous report, romosozumab was generally well tolerated, with no new safety  
273 findings observed (24). The most frequently observed adverse events were injection site reactions, which  
274 some patients experienced multiple times. While two severe events were noted, the frequency of these  
275 events was similar to previous studies (24,38). Although safety concerns, including cardiovascular risk,  
276 were raised by romosozumab when compared with alendronate, this risk was not observed in a placebo-  
277 controlled trial (24,41,46). In addition, recent studies have shown that romosozumab is not associated  
278 with an increased rate of adverse events, regardless of levels of kidney function (47). Nevertheless,  
279 careful assessment, including the risk of a cardiovascular event, is desired prior to romosozumab  
280 initiation. Moreover, the safety profiles of osteoporosis treatment need to be assessed in the perioperative  
281 setting.

282 This study has several limitations. The first is the non-randomized, open-label design, which was  
283 necessitated by the differential effectiveness of each drug in preventing fractures, particularly among our  
284 study population, which consisted of patients with relatively severe osteoporosis. Consequently, patient  
285 choice followed expert consultation, leading to a disparity in the number of patients in each group. While  
286 there was an open-label nature of the treatment assignments, the primary outcomes were measured by  
287 investigators who were masked to the group allocation. Another limitation was the small samples size,  
288 affecting our power to detect differences between groups. However, the romosozumab groups exhibited  
289 significant improvement in primary outcomes, and the sample size was relatively large compared to  
290 previous implant-related FEM studies (18,32). In addition, although FEM have been validated in earlier  
291 study, our FEM model could not fully mimic the clinical situation (32). Nevertheless, conducting damage  
292 or destruction analysis in the clinical setting is inherently impractical. Finally, we were unable to evaluate

293 bone fusion and reoperation rates, one of the endpoints of spinal instrumentation surgery. Nonetheless,  
294 both the rigid screw fixation and reduced cage subsidence were potentially facilitated by romosozumab,  
295 and thus could beneficially contribute to bone fusion. Further study is warranted to support this notion.

296 The strengths of this study include the use of a variety of complementary imaging modalities to evaluate  
297 the effect of romosozumab on instrumentations surgery, yielding consistent and complementary results.  
298 Throughout our novel biomechanical approach, we first established the impact of instrumentation surgery  
299 based on the region-specific BMD alternations observed following romosozumab treatment. Such  
300 assessments are often a challenge for traditional biomechanical methods, particularly when drugs are  
301 involved in the clinical setting. While the present findings highlight a unique benefit of romosozumab for  
302 patients with osteoporosis undergoing instrumentation surgery, it is imperative to standardize a  
303 multidisciplinary approach, including osteoporosis assessment and treatment, prior to implantation  
304 surgery in order to maximize the chance of securing long-term success.

305

### 306 **Acknowledgements**

307 We would like to express our sincere gratitude to the staff at the Department of Orthopaedic Surgery at  
308 Showa University for their helpful discussion and assistance. We are also grateful to Hideyuki Mimata  
309 for the valuable technical assistance. Finally, we thank Ayano Oyamada, Kei Gonsoho and Miho  
310 Mochizuki for their cooperation in collecting clinical data.

## 311 References

- 312 1. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al. Estimate of the  
313 global volume of surgery in 2012: an assessment supporting improved health outcomes. *Lancet*.  
314 2015;385:S11.
- 315 2. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and  
316 national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for  
317 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease  
318 Study 2017. *Lancet*. 2018;392(10159):1789–858.
- 319 3. Etzioni DA, Liu JH, Maggard MA, Ko CY. The Aging Population and Its Impact on the Surgery  
320 Workforce. *Ann Surg*. 2003;238(2):170–7.
- 321 4. Punnoose A, Claydon-Mueller LS, Weiss O, Zhang J, Rushton A, Khanduja V. Prehabilitation for  
322 Patients Undergoing Orthopedic Surgery: A Systematic Review and Meta-analysis. *JAMA Netw*  
323 *Open*. 2023;6(4):E238050.
- 324 5. Keaveny TM, Adams AL, Fischer H, Brara HS, Burch S, Guppy KH, et al. Increased risks of  
325 vertebral fracture and reoperation in primary spinal fusion patients who test positive for  
326 osteoporosis by Biomechanical Computed Tomography analysis. *Spine J [Internet]*.  
327 2023;23(3):412–24. Available from: <https://doi.org/10.1016/j.spinee.2022.10.018>
- 328 6. Ishikawa K, Toyone T, Shirahata T, Kudo Y, Matsuoka A, Maruyama H, et al. A Novel Method  
329 for the Prediction of the Pedicle Screw Stability. *Clin Spine Surg*. 2018;31(9):E473–80.
- 330 7. Bliuc D, Nguyen ND, Milch VE, Nguyen T V., Eisman JA, Center JR. Mortality risk associated  
331 with low-trauma osteoporotic fracture and subsequent fracture in men and women. *JAMA*.  
332 2009;301(5):513–21.
- 333 8. Center JR, Bliuc D, Nguyen ND, Nguyen T V., Eisman JA. Osteoporosis medication and reduced  
334 mortality risk in elderly women and men. *J Clin Endocrinol Metab*. 2011;96(4):1006–14.
- 335 9. Abrahamsen B, Osmond C, Cooper C. Osteoporosis: Treat or let die twice more likely. *J Bone*  
336 *Miner Res*. 2015;30(9):1553–9.
- 337 10. Miller AN, Lake AF, Emory CL. Establishing a fracture liaison service: An orthopaedic approach.  
338 *J Bone Jt Surg - Am Vol*. 2015;97(8):675–81.
- 339 11. Sardar ZM, Coury JR, Cerpa M, Dewald CJ, Ames CP, Shuhart C, et al. Best Practice Guidelines  
340 for Assessment and Management of Osteoporosis in Adult Patients Undergoing Elective Spinal  
341 Reconstruction. *Spine (Phila Pa 1976)*. 2022;47(2):128–35.
- 342 12. Lubelski D, Choma TJ, Steinmetz MP, Harrop JS, Mroz TE. Perioperative medical management  
343 of spine surgery patients with osteoporosis. *Neurosurgery*. 2015;77(4):S92–7.
- 344 13. Zhang A, Khatri S, Balmaceno-Criss M, Alsoof D, Daniels AH. Medical optimization of  
345 osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current  
346 pharmacotherapy. *Spine Deform [Internet]*. 2022;11(3):579–96. Available from:  
347 <https://doi.org/10.1007/s43390-022-00621-6>
- 348 14. Chang HK, Ku J, Ku J, Kuo YH, Chang CC, Wu CL, et al. Correlation of bone density to screw  
349 loosening in dynamic stabilization: an analysis of 176 patients. *Sci Rep [Internet]*. 2021;11(1):1–7.  
350 Available from: <https://doi.org/10.1038/s41598-021-95232-y>
- 351 15. Bredow J, Boese CK, Werner CML, Siewe J, Löhner L, Zarghooni K, et al. Predictive validity of  
352 preoperative CT scans and the risk of pedicle screw loosening in spinal surgery. *Arch Orthop*  
353 *Trauma Surg*. 2016;136(8):1063–7.

- 354 16. Pearson HB, Dobbs CJ, Grantham E, Niebur GL, Chappuis JL, Boerckel JD. Intraoperative  
355 biomechanics of lumbar pedicle screw loosening following successful arthrodesis. *J Orthop Res.*  
356 2017;35(12):2673–81.
- 357 17. Kaiser J, Allaire B, Fein PM, Lu D, Adams A, Kiel DP, et al. Heterogeneity and Spatial  
358 Distribution of Intravertebral Trabecular Bone Mineral Density in the Lumbar Spine Is Associated  
359 With Prevalent Vertebral Fracture. *J Bone Miner Res.* 2020;35(4):641–8.
- 360 18. Tani S, Ishikawa K, Kudo Y, Tsuchiya K, Matsuoaka A, Maruyama H, et al. The effect of  
361 denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element  
362 analysis. *J Orthop Surg Res.* 2021;16(1):1–10.
- 363 19. Parisien A, Wai EK, Elsayed MSA, Frei H. Subsidence of Spinal Fusion Cages: A Systematic  
364 Review. *Int J Spine Surg.* 2022;16(6):1103–18.
- 365 20. Zhang Y, Jiang Y, Zou D, Yuan B, Ke HZ, Li W. Therapeutics for enhancement of spinal fusion:  
366 A mini review. *J Orthop Transl.* 2021 Nov 1;31:73–9.
- 367 21. Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, et al. Role of weekly  
368 teriparatide administration in osseous union enhancement within six months after posterior or  
369 transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders:  
370 A multicenter, prospective randomized study. *J Bone Jt Surg - Am Vol* [Internet]. 2017 [cited  
371 2022 May 28];99(5):365–72. Available from:  
372 [https://journals.lww.com/jbjsjournal/Fulltext/2017/03010/Role\\_of\\_Weekly\\_Teriparatide\\_Adminis](https://journals.lww.com/jbjsjournal/Fulltext/2017/03010/Role_of_Weekly_Teriparatide_Administration_in.1.aspx)  
373 [tration\\_in.1.aspx](https://journals.lww.com/jbjsjournal/Fulltext/2017/03010/Role_of_Weekly_Teriparatide_Administration_in.1.aspx)
- 374 22. Yagi M, Ohne H, Konomi T, Fujiyoshi K, Kaneko S, Komiyama T, et al. Teriparatide improves  
375 volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone  
376 failure type PJK after surgery for adult spinal deformity. *Osteoporos Int* [Internet].  
377 2016;27(12):3495–502. Available from: <http://dx.doi.org/10.1007/s00198-016-3676-6>
- 378 23. Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, et al. Comparison of teriparatide  
379 and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery  
380 in postmenopausal women with osteoporosis from a bone quality perspective. *Spine (Phila Pa*  
381 *1976).* 2013;38(8):487–92.
- 382 24. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab  
383 Treatment in Postmenopausal Women with Osteoporosis. *N Engl J Med.* 2016;375(16):1532–43.
- 384 25. Graeff C, Campbell GM, Peña J, Borggrefe J, Padhi D, Kaufman A, et al. Administration of  
385 romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative  
386 computed tomography and finite element analysis. *Bone* [Internet]. 2015;81:364–9. Available  
387 from: <http://dx.doi.org/10.1016/j.bone.2015.07.036>
- 388 26. Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, et al. Bone-Forming  
389 and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone  
390 Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of  
391 Treatment. *J Bone Miner Res.* 2019;34(9):1597–608.
- 392 27. Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, et al. Japanese 2011 guidelines for  
393 prevention and treatment of osteoporosis-executive summary. *Arch Osteoporos.* 2012;7(1–2):3–  
394 20.
- 395 28. Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, et al. High bone turnover elevates the  
396 risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. *Ther Clin*  
397 *Risk Manag.* 2016;12:1831–40.
- 398 29. Tsuchiya K, Ishikawa K, Kudo Y, Tani S, Nagai T, Toyone T, et al. Analysis of the subsequent

- 399 treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative  
400 computed tomography: A prospective cohort study. *Bone Reports* [Internet].  
401 2021;14(April):101090. Available from: <https://doi.org/10.1016/j.bonr.2021.101090>
- 402 30. Kuroda T, Ishikawa K, Nagai T, Fukui T, Hirano T, Inagaki K. Quadrant Analysis of Quantitative  
403 Computed Tomography Scans of the Femoral Neck Reveals Superior Region-Specific Weakness  
404 in Young and Middle-Aged Men With Type 1 Diabetes Mellitus. *J Clin Densitom* [Internet].  
405 2018;21(2):172–8. Available from: <https://doi.org/10.1016/j.jocd.2017.01.005>
- 406 31. Harry K Genant, Chun Y Wu, Corner Van Kuijk, Michael C Nevitt. Using a Semiquantitative  
407 Technique. *J Bone Miner Res*. 1993;8(9):1137–48.
- 408 32. Matsuura Y, Giambini H, Ogawa Y, Fang Z, Thoreson AR, Yaszemski MJ, et al. Specimen-  
409 specific nonlinear finite element modeling to predict vertebrae fracture loads after vertebroplasty.  
410 *Spine (Phila Pa 1976)*. 2014;39(22):E1291–6.
- 411 33. Arsen M Pankovich, Imad E Tarabishy. Remote nailing of intertrochanteric and subtrochanteric  
412 fractures of the femur. *Instr Course Lect*. 1983;32(4):303–16.
- 413 34. Laros GS. The role of osteoporosis in intertrochanteric fractures. *Orthop Clin North Am* [Internet].  
414 1980;11(3):525–37. Available from: [http://dx.doi.org/10.1016/S0030-5898\(20\)31455-3](http://dx.doi.org/10.1016/S0030-5898(20)31455-3)
- 415 35. Keiler A, Schmoelz W, Erhart S, Gnanalingham K. Primary stiffness of a modified transforaminal  
416 lumbar interbody fusion cage with integrated screw fixation: Cadaveric biomechanical study.  
417 *Spine (Phila Pa 1976)*. 2014;39(17).
- 418 36. Fu X, Tan J, Sun CG, Leng HJ, Xu YS, Song CL. Intraosseous injection of simvastatin in  
419 poloxamer 407 hydrogel improves pedicle-screw fixation in ovariectomized minipigs. *J Bone Jt*  
420 *Surg - Am Vol*. 2016;98(22):1924–32.
- 421 37. Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, et al. Romosozumab  
422 improves lumbar spine bone mass and bone strength parameters relative to alendronate in  
423 postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal  
424 Women With Osteoporosis at High Risk (ARCH) trial. *J Bone Miner Res*. 2021;36(11):2139–52.
- 425 38. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al.  
426 Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women  
427 with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase  
428 3 trial. *Lancet* [Internet]. 2017;390(10102):1585–94. Available from:  
429 [http://dx.doi.org/10.1016/S0140-6736\(17\)31613-6](http://dx.doi.org/10.1016/S0140-6736(17)31613-6)
- 430 39. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges.  
431 *lancet Diabetes Endocrinol*. 2017 Nov;5(11):898–907.
- 432 40. Xu H, Wang W, Liu X, Huang W, Zhu C, Xu Y, et al. Targeting strategies for bone diseases:  
433 signaling pathways and clinical studies. *Signal Transduct Target Ther* [Internet]. 2023;8(1):202.  
434 Available from:  
435 <http://www.ncbi.nlm.nih.gov/pubmed/37198232> [http://www.pubmedcentral.nih.gov/articleren](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC10192458)  
436 [der.fcgi?artid=PMC10192458](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC10192458)
- 437 41. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or  
438 Alendronate for Fracture Prevention in Women with Osteoporosis. *N Engl J Med*.  
439 2017;377(15):1417–27.
- 440 42. Rand T, Seidl G, Kainberger F, Resch A, Hittmair K, Schneider B, et al. Impact of spinal  
441 degenerative changes on the evaluation of bone mineral density with dual energy X-ray  
442 absorptiometry (DXA). *Calcif Tissue Int*. 1997;60(5):430–3.



- 443 43. Poole KES, Treece GM, Pearson RA, Gee AH, Bolognese MA, Brown JP, et al. Romosozumab  
444 Enhances Vertebral Bone Structure in Women With Low Bone Density. *J Bone Miner Res.*  
445 2022;37(2):256–64.
- 446 44. Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, et al. Effects of  
447 Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in  
448 Postmenopausal Women With Low Bone Mass. *J Bone Miner Res.* 2017;32(1):181–7.
- 449 45. Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, et al. Modeling-Based Bone  
450 Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.  
451 *J Bone Miner Res.* 2022;37(1):36–40.
- 452 46. Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Effectiveness and Safety of Treatments  
453 to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living  
454 Systematic Review and Network Meta-analysis for the American College of Physicians. *Ann*  
455 *Intern Med.* 2023;176(2):182–95.
- 456 47. Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, et al. Efficacy and  
457 Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-  
458 Moderate Chronic Kidney Disease. *J Bone Miner Res.* 2022;37(8):1437–45.

459

460 **Table 1. Baseline patient characteristics.**

Parameters	All	Romo	ELD
Age (years)	76.0 (70.0 / 81.3)	77.0 (70.0 / 82.3)	70.0 (75.0 / 66.5)
Male (%)	5 (6.9)	4 (5.8)	1 (8.3)
BMI	21.5 (19.6 / 23.4)	21.3 (19.5 / 23.1)	23.2 (21.5 / 24.6)
Fracture history (%)	51 (63.0)	46 (56.8)	5 (41.7)
Smoking (%)	5 (6.2)	3 (4.3)	2 (16.7)
Alcohol (%)	4 (4.9)	3 (4.3)	1 (8.3)
<b>Prior treatment</b>			
None	45 (55.6)	34 (49.3)	11 (91.7)
Bisphosphonate	11 (13.6)	11 (15.9)	0 (0)
SERM	3 (3.7)	3 (4.3)	0 (0)
Denosumab	10 (12.3)	10 (14.5)	0 (0)
Teriparatide	12 (14.8)	11 (15.9)	1 (8.3)
<b>Blood samples</b>			
Albumin levels (g / dl)	4.3 (4.1 / 4.5)	4.3 (4.1 / 4.5)	4.4 (4.2 / 4.6)
Corrected calcium levels (mg / dl)	9.4 (9.1 / 9.5)	9.4 (9.2 / 9.5)	9.2 (9.0 / 9.5)
Phosphorus levels (mg / dl)	3.6 (3.2 / 4.1)	3.6 (3.2 / 4.1)	3.6 (3.5 / 4.0)
eGFR (mL / min / 1.73m <sup>2</sup> )	66.0 (55.0 / 74.0)	66.0 (54.8 / 74.0)	68.5 (61.5 / 75.0)
<b>Bone metabolic markers</b>			
total-P1NP (µg / ml)	58.6 (31.3 / 86.2)	55.0 (29.2 / 81.0)	74.1 (58.6 / 115.4)
TRACP-5b (mU / dL)	453.0 (287.3 / 571.3)	428.0 (268.8 / 560.5)	536.5 (453.0 / 689.0)
<b>Bone mineral density</b>			
Spine- aBMD (g / cm <sup>2</sup> )	0.75 (0.67 / 0.83)	0.75 (0.66 / 0.83)	0.77 (0.73 / 0.85)
Vertebral- vBMD (mg / cm <sup>3</sup> )	77.5 (59.5 / 91.7)	76.8 (57.5 / 91.0)	79.3 (76.2 / 95.7)
Pedicle - vBMD (mg / cm <sup>3</sup> )	126.1 (93.1 / 145.0)	122.4 (92.3 / 143.1)	138.0 (109.4 / 154.8)

461 There were no statistical differences between groups for any of the parameters.

462 The data shown are the median (interquartile ranges [IQR]; Q1/Q3) or n (%). The data shown as n or n

463 (%) were analyzed by Fisher's exact test. The data presented as median IQR were analyzed by Mann-

464 Whitney U test.

465 BMI; bone mass index, SERM; selective estrogen receptor modulator, eGFR; estimated glomerular

466 filtration rate, total-P1NP; total N-terminal propeptide of type 1 procollagen, TRACP-5P; tartrate-

467 resistant acid phosphatase type 5 protein, aBMD; areal bone mineral density, vBMD; volumetric bone  
468 mineral density.

469 **Table2. The regional BMD is well correlated with the biomechanical parameters.**

Baseline		Vertebral strength		Pullout strength		Cage subsidence strength	
		r	p	r	p	r	p
All	Spine- aBMD (g / cm <sup>2</sup> )	0.2640	0.0180	0.2926	0.0080	0.1103	0.3301
	Vertebral- vBMD (mg / cm <sup>3</sup> )	0.6387	< 0.0001	0.5096	< 0.0001	0.6108	< 0.0001
	Pedicle - vBMD (mg / cm <sup>3</sup> )	0.5253	< 0.0001	0.6706	< 0.001	0.3463	0.0017
Romo	Spine- aBMD (g / cm <sup>2</sup> )	0.2959	0.0143	0.3409	0.0042	0.1145	0.3524
	Vertebral- vBMD (mg / cm <sup>3</sup> )	0.6706	< 0.0001	0.4814	< 0.0001	0.5635	< 0.0001
	Pedicle - vBMD (mg / cm <sup>3</sup> )	0.5342	< 0.0001	0.6253	< 0.0001	0.2814	0.0201
ELD	Spine- aBMD (g / cm <sup>2</sup> )	0.1191	0.7124	-0.0424	0.8956	0.1189	0.7129
	Vertebral- vBMD (mg / cm <sup>3</sup> )	0.4308	0.1621	0.1414	0.6613	0.8531	0.0004
	Pedicle - vBMD (mg / cm <sup>3</sup> )	0.4308	0.1621	0.9188	< 0.0001	0.6573	0.0202
3 months		Vertebral strength		Pullout strength		Cage subsidence strength	
		r	p	r	p	r	P
All	Vertebral- vBMD (mg / cm <sup>3</sup> )	0.7106	< 0.0001	0.5470	< 0.0001	0.6294	< 0.0001
	Pedicle - vBMD (mg / cm <sup>3</sup> )	0.5805	< 0.0001	0.6946	< 0.0001	0.3896	0.0004
Romo	Vertebral- vBMD (mg / cm <sup>3</sup> )	0.7474	< 0.0001	0.5324	< 0.0001	0.6177	< 0.0001
	Pedicle - vBMD (mg / cm <sup>3</sup> )	0.5854	< 0.0001	0.6658	< 0.0001	0.3421	0.0043
ELD	Vertebral- vBMD (mg / cm <sup>3</sup> )	0.8392	0.0006	0.7874	0.0024	0.8392	0.0006
	Pedicle - vBMD (mg / cm <sup>3</sup> )	0.4755	0.1182	0.8647	0.0003	0.7413	0.0006

470


471 Correlations of the biomechanical parameters and BMD measured by DXA (aBMD) and QCT (vBMD).

472 The biomechanical parameters exhibited significant correlations with each BMD measurement and

473 showed a stronger correlation with the regional vBMD measured by QCT.

474 aBMD: areal bone mineral density, vBMD: volumetric bone mineral density

475 **Figure1. Overview of *in silico* drug assessment for instrumentation surgery**



476

477 The proposed framework for drug assessment in instrumentation surgery.


478 **a**, CT scans, pre- and post-treatment, with a calibration phantom for quality longitudinal measurements.

479 **b**, Creation of the 3D (dimensional) vertebral models from the CT data. **c**, Regional 3D v-BMD

480 measurements provide accurate BMD assessment. **d**, Biomechanical evaluations of surgical-related


481 parameters using the finite element method.

482 **Figure2. Romosozumab rapidly increases vBMD in the vertebral body and pedicle.**



483 **a**, Image illustrating the 3D model of the vertebrae and dimensions in both the axial and sagittal views.  
484 Color map representing the distribution of bone mineral density ( $\text{mg}/\text{mm}^3$ ). **b**, Representative axial  
485 images of BMD distribution at baseline and 3 months. **c**, Enlarged images of the axial view of the pedicle  
486 and vertebral body showing the improvement in BMD with romosozumab treatment in both the pedicle  
487 and vertebral body. **d**, Representative sagittal images of BMD at baseline and 3 months. **e**, Enlarged  
488 images of the sagittal view of the cage's corresponding area and inner cortical region of the pedicle,  
489 showing the BMD increase with romosozumab. **f**, **g**, Percentage changes of vertebral-vBMD and pedicle-  
490 vBMD between groups following 3 months of treatment. Data are expressed as medians (interquartile  
491 ranges). Differences between groups were analyzed using Mann–Whitney U test. \*:  $P < 0.05$ , \*\*:  $P <$   
492  $0.01$ , \*\*\*:  $P < 0.001$ , \*\*\*\*:  $P < 0.0001$ . vBMD: volumetric bone mineral density

493 **Figure3. Romosozumab resulted in improvement in all the biomechanical analyses**



494

495 **a**, Representative images illustrating the compression strength analysis under a 3500 N load, following  
 496 treatment. The upper images depict the distribution of yield risk (%), while the lower images show the  
 497 distribution of elements associated with high-risk crushing [yield elements (yellow) and compressive  
 498 failure elements (red)] both at baseline and 3 months. High yield risk and an increase in crushed elements  
 499 suggest the potential risk of vertebral fracture. **b**, Representative images showing the pullout strength  
 500 analysis results when a 200 N force was applied to extract the screw. The upper images depict the  
 501 distribution of yield risk (%), while the lower images show the distribution of elements associated with



502 high-risk crushing. High yield risk and an increase in crushed elements suggest a potential risk of screw  
503 loosening. **c**, Representative images illustrating the cage subsidence strength when a load of 400 N was  
504 applied. The upper images depict the distribution of yield risk (%), while the lower images show the  
505 distribution of elements associated with high-risk crushing. High yield risk and an increase in crushed  
506 elements suggest a potential risk of cage subsidence. **d-e**, Percentage changes in biomechanical  
507 parameters between groups following 3 months of treatment. Data are expressed as medians  
508 (interquartile ranges). Differences between groups were analyzed using Mann–Whitney U test. \*: P <  
509 0.05, \*\*: P < 0.01, \*\*\*: P < 0.001.

510 **Supplemental Information (Table S1, Figure S1-6, Movie S1-4)**

511

512 **The potential effect of romosozumab on perioperative management for**  
513 **instrumentation surgery**

514

515 Koji Ishikawa<sup>1,2,3\*</sup>, Soji Tani<sup>1</sup>, Koki Tsuchiya<sup>1</sup>, Tomoko Towatari<sup>1</sup>, Yusuke Oshita<sup>4</sup>, Ryo Yamamura<sup>1</sup>,  
516 Toshiyuki Shirahata<sup>2</sup>, Katsunori Inagaki<sup>1</sup>, Tomoaki Toyone<sup>1</sup>, Yoshifumi Kudo<sup>1</sup>

517

518 <sup>1</sup> Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan

519 <sup>2</sup> Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan

520 <sup>3</sup> Department of Orthopaedic Surgery, Duke University, North Carolina, USA

521 <sup>4</sup> Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital, Kanagawa, Japan

522 <sup>5</sup> Department of Orthopaedic Surgery, Showa University Koto Toyosu Hospital

523

524 **\*Corresponding author:** Koji Ishikawa (K.I)

525 Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan

526 Address: Building No.6, room517, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan

527 Tel: +81 3 3784 8543 Fax: +81 3 3784 9005

528 Email: [koji.ishikawa@med.showa-u.ac.jp](mailto:koji.ishikawa@med.showa-u.ac.jp)

529

530 **Supplemental table1 Materials properties of each element for finite element models**

	Young's Modulus (E) (MPa)	Poisson's Ratio	Yield Stress ( $\sigma$ ) (MPa)	Critical Stress (MPa)	Element type	Size/Thickness
Bone	Keyak (equation 1)	0.4	Keyak (equation 2)	St = 0.8Sm	Tetrahedral solid	Less than 2 mm / -
Cortical shell	*	0.4	Keyak (equation 2)	St = 0.8Sm	Triangular plate	2 mm / 0.4 mm
Cement cap (PMMA)	2500	0.35	20.6	75.0	Tetrahedral solid	2 mm / -
Pedicle screw (Titanium alloy)	108853.8	0.28	899.3	824.7	Tetrahedral solid	Less than 1 mm / -
Cage (PEEK)	3.6	0.3	90.0	90.0	Tetrahedral solid	Less than 1 mm / -

**Equation 1**

$$E = \begin{cases} 0.001(\rho = 0) \\ 33900\rho^{2.20} (0 < \rho \leq 0.27) \\ 5307\rho + 469(0.28 < \rho < 0.6) \\ 10200\rho^{2.01}(0.6 \leq \rho) \end{cases}$$

**Equation 2**


$$\sigma = \begin{cases} 1.0 * 10^{20}(\rho \leq 0.2) \\ 137\rho^{1.88} (0.2 < \rho < 0.317) \\ 114\rho^{1.72} (0.317 < \rho) \end{cases}$$

531

532 \*Young's Modulus of the cortical shell was determined by the Hounsfield unit, selecting the value of its  
533 adjacent bone unless it was lower than 1000, in which case a value of 1000 was used.

534 PMMA; poly(methyl-methacrylate), PEEK; polyetheretherketone

535 **Supplemental figure 1. The regions of interest for both pedicle-vBMD and vertebral-vBMD.**




536

537 The red and blue areas illustrate the ROI of the pedicle-vBMD and vertebral-vBMD, respectively. The  
538 ROI for the pedicle-vBMD and vertebral-vBMD were manually defined so as to cover the corresponding  
539 area, consistent with previous reports (6,18).

540 ROI: region of interest, vBMD: volumetric bone mineral density.

541 **Supplemental figure2. Study diagram**


542



543

544 Between March 2019 and March 2021, 400 patients had osteoporosis treatment. 226 patients who were  
545 scheduled for romosozumab (Romo) or eldecalcitol (ELD) treatment were assessed for inclusion, with 81  
546 participating in the present study. Patients were divided into two groups based on their treatment (Romo:  
547 69 patients, ELD: 12 patients), and 66 patients (95.7%) from the Romo group and 10 patients (83.3%)  
548 from the ELD group completed 6 month follow-up.


549 **Supplemental figure3. Safety profile of romosozumab treatment for 6 months**



550

551 The incidence rate of adverse events during 6 months of romosozumab treatment. Blue dots represent  
552 patients without any adverse events, whereas the orange dots represent patients who experienced adverse  
553 events. Twenty-one patients (30.4%) experienced adverse events following romosozumab treatment.  
554 Injection-site reactions were reported by 16 patients (23.2%). Hypocalcemia and hypercalcemia were  
555 observed in one patient each (1.5%), respectively. Gastroenteritis was reported by one patient (1.5%).  
556 Two (2.9%) patients having severe adverse events included one stroke and one death leading to  
557 discontinuation of treatment. These severe adverse events were not thought to be associated with the  
558 treatment.

559 **Supplemental figure4. Overview of injection site reactions during romosozumab treatment**



560

561 **a**, Distribution of injection site reactions. **b**, Proportion of patients experienced multiple injection site  
562 reactions.


563 Twenty-two injection-site reactions were reported in 16 patients (23.2%) in the romosozumab group.

564 These reactions were most common at the initial injection (50.0%). Among the patients who had

565 injection-site reactions, five patients (7.3%) experienced these reactions multiple times (2 times: 4

566 patients, 3 times: 1 patient) during the course of the study.

567 **Supplemental figure5. Changes in bone turnover markers during the 6-month treatment**



568

569 **a**, Percentage change from baseline in total P1NP. **b**, Absolute change from baseline in total P1NP, **c**,

570 Percentage change from baseline in TRACP-5b. **d**, Absolute change from baseline in TRACP-5b.

571 In the Romo group, the P1NP level peaked at 3 months, and the percentage change from baseline of total

572 P1NP was higher compared to the ELD group at both 3 and 6 months. The TRACP-5b levels decreased

573 significantly in both groups, with no significant difference observed between the groups. Data are

574 expressed as medians (interquartile ranges). The difference in the continuous measures across the groups

575 was compared using a one-way analysis by the Dunn test. Differences between groups were analyzed

576 using the Mann–Whitney U test. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ , \*\*\*\*:  $P < 0.0001$ , ns: not


577 significant.

578 total P1NP: total N-terminal propeptide of type 1 procollagen, TRACP-5b: tartrate-resistant acid

579 phosphatase 5b.



580 **Supplemental figure6. Spine-aBMD assessed by DXA increased significantly following**  
581 **romosozumab treatment at 6 months.**



582

583 Percentage changes of spine-aBMD between groups following 6 months of treatment.

584 **a**, Percentage change in all patients. **b**, Percentage change in patients with treatment naïve.

585 aBMD: areal bone mineral density

586 **Supplemental Movie1. The modeling methods of a 3D vertebra**

587 A 3D model of the spine was created based on the CT data, then the L4 vertebra was constructed with  
588 2mm tetrahedral solid elements and 2-mm triangular plates using MECHANICAL FINDER software  
589 (version 12.0 extended edition; Research Center of Computational Mechanics, Tokyo, Japan). Each  
590 element was assigned individual mechanical properties, and the bone mineral density was integrated to  
591 account for bone heterogeneity.

592 **Supplemental Movie2. Finite element analysis for compression strength**

593 A compressive displacement was applied to the PMMA (poly methyl-methacrylate) cement cap at the  
594 cranial end of the vertebrae, with displacement increments of 0.01 mm / step. The time segment from  
595 0:07-0:17 depicts the distribution of high-risk elements associated with crushing [yield elements (yellow)  
596 and compressive failure elements (red)], while 0:18-0:41 illustrates the distribution of yield risk. High  
597 yield risk and an increase in compressive failure elements suggest a potential risk for compression  
598 fracture.

599 **Supplemental Movie3. Finite element analysis for pullout strength**

600 A screw was implanted according to the conventional pedicle screw trajectory. The vertebra was fully  
601 fixed in all directions, and an incremental tensile loading rate of 20 Newton (N) / step was applied to the  
602 screw head. From 0:06-0:17 the images show the distribution of high-risk elements associated with  
603 crushing [yield elements (yellow) and compressive failure elements (red)], while 0:18-0:30 illustrates the  
604 distribution of yield risk. High yield risk and an increase in compressive failure elements suggest a  
605 potential risk for compression fracture.

606 **Supplemental Movie4. Finite element analysis for cage subsidence strength**

607 A PEEK (polyetheretherketone) cage was positioned 5-mm behind the anterior edge of the upper endplate  
608 vertebrae to assess the risk of cage subsidence. A compressive displacement was applied to the PEEK  
609 cage at the cranial end of the vertebrae, using ramped displacement increments of 0.01 mm / step. The

610 time segment of the 0:05-0:15 images shows the distribution of high-risk elements associated with  
611 crushing [yield elements (yellow) and compressive failure elements (red)], while 0:20-0:30 illustrates the  
612 distribution of yield risk. High yield risk and an increase in compressive failure elements suggest a  
613 potential risk of cage subsidence.

614